<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162081</url>
  </required_header>
  <id_info>
    <org_study_id>NRC256431WP2</org_study_id>
    <nct_id>NCT03162081</nct_id>
  </id_info>
  <brief_title>Medication Misuse and Dependence Among Elderly</brief_title>
  <official_title>Medication Misuse and Dependence in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project focuses on investigating problematic medication use, especially overuse of
      potentially addictive drugs among the elderly.

      The investigators aim firstly to develop and validate instruments for detecting and
      describing behavioral aspects and consequences of dependence on, and misuse of, prescription
      medication among elderly.

      In addition to evaluating diagnostic utility of screening instruments, the investigators aim
      to identify and report characteristics, risk factors and consequences of medication misuse
      and dependence among the elderly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elderly represent a particularly vulnerable group with many contributing factors including
      age-related multifactorial morbidity, cognitive function, polypharmacy, dependence and
      multiple prescribers with suboptimal communication. Centrally active pain killers and
      sedative/hypnotic medications give increased risk of addiction, adverse drug events, reduced
      physical and/or cognitive function.

      The project comprises diagnostic accuracy, descriptive screening, cross-sectional and
      case-control studies, with aims to: i) assess diagnostic utility of instruments for elderly
      patients; ii) describe risk factors for medication misuse and dependence; iii) describe
      consequences of the use of centrally active medications among elderly compared to a control
      population.

      Moreover, the investigators aim to examine the association between medication misuse and
      changes in cognitive function, focusing on deficits in specific domains of cognition. An
      additional aim is to explore the possibility of dissociating such cognitive changes from
      other causes of mild cognitive impairment (MCI) associated with development of dementia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>2 Weeks</target_duration>
  <primary_outcome>
    <measure>Dependence y/n</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>DSM-IV defined substance dependence assessed by MINI interview</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication misuse y/n</measure>
    <time_frame>Past year prior to in-hospital stay (data collected within 2 weeks of admission)</time_frame>
    <description>Use of any of: opiates/benzodiazepine/Z-hypnotics &gt;5 days per week for &gt;3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MCI - Mild cognitive impairment</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Defined by MMSE &lt; 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Numerical score of cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COGNISTAT</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Cognitive profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS-11</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Impulsivity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS/BAS score</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Behavioura inhibition/activation score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TUG</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Functional test score (time in secs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLB</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Functional test score (time in secs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological profiles</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Tests as listed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of addictive medication y/n</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>Prescription use of any of the following: opiates, benzodiazepines, Z-hypnotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No of days of use of defined addictive medications/month</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No. days of use of any of the following: opiates, benzodiazepines, Z-hypnotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of possible side effects</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No. possible side effects of any of the following: opiates, benzodiazepines, Z-hypnotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of possible serious interactions</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No. possible serious interactions of any of the following: opiates, benzodiazepines, Z-hypnotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No.of inappropriate medications for elderly at admission</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No.of inappropriate medications as defined by NORGEP criteria (Norwegian general practice criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No.of inappropriate medications for elderly during in-hospital stay</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No.of inappropriate medications as defined by NORGEP criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No.of inappropriate medications for elderly at discharge</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No.of inappropriate medications as defined by NORGEP criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No.of inappropriate medications for elderly at admission</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No.of inappropriate medications as defined by STOPP criteria (Screening tool of older patients prescriptions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No.of inappropriate medications for elderly during in-hospital stay</measure>
    <time_frame>Within 2 weeks of admission</time_frame>
    <description>No.of inappropriate medications as defined by STOPP criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No.of inappropriate medications for elderly at discharge</measure>
    <time_frame>Within 2 weeks (index stay may in some cases be somewhat longer)</time_frame>
    <description>No.of inappropriate medications as defined by STOPP criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substance use disorder</measure>
    <time_frame>Within 2 weeks</time_frame>
    <description>DSM-IV criteria assessed through additional questions to MINI interview</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Elderly</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Users</arm_group_label>
    <description>Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates
Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-users</arm_group_label>
    <description>Age and gender matched controls not using the above
Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Screening group</arm_group_label>
    <description>Patients over 65 admitted to hospital as in-patients
Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Substance misuse screening</intervention_name>
    <description>Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EQ-5D</intervention_name>
    <description>Health related Quality of life</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Impulsivity screening</intervention_name>
    <description>Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cognitive screening</intervention_name>
    <description>Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Functional tests</intervention_name>
    <description>Timed up and go (TUG), Single leg balancing test (SLB)</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cognistat</intervention_name>
    <description>Assessment of cognitive domains</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neuropsychological profiling</intervention_name>
    <description>Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical interview</intervention_name>
    <description>Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication use</intervention_name>
    <description>Detailed screen of used medications, interactions, side effects in electronic patient registry</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comorbidity</intervention_name>
    <description>Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry</description>
    <arm_group_label>Users</arm_group_label>
    <arm_group_label>Non-users</arm_group_label>
    <arm_group_label>Screening group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All admitted elderly 65-90 years of age are screened, for case-control age and
        gender-matched pairs of Users and non-users will in addition be examined in depth with
        neuropsychological tests
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to geriatric or Neurology dept of hospital during inclusion time

        Exclusion Criteria:

          -  MMSE &lt; 21,

          -  diagnosis of pre-existing severe depression or psychotic disease,

          -  pre-existing dementia diagnosis,

          -  new pain requiring start-up of central pain killers not previously used,

          -  Palliative treatment.

          -  Insufficient Norwegian language

          -  Serious visual disturbance and hearing impairment

          -  Strongly reduced general health precluding partcipation in interview and
             questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorunn Rugkåsa, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Coordinator of overall research program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christofer Lundqvist, PhD</last_name>
    <phone>+47-47278881</phone>
    <email>a.c.lundqvist@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Socheat Cheng, M.D.</last_name>
    <phone>+47-45063936</phone>
    <email>socc@ahus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Lundqvist, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christofer Lundqvist, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Socheat Cheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Christofer Lundqvist</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>addiction</keyword>
  <keyword>cognition</keyword>
  <keyword>impulsivity</keyword>
  <keyword>neuropsychology</keyword>
  <keyword>prescription drug misuse</keyword>
  <keyword>dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

